Pages that link to "Q34483086"
Jump to navigation
Jump to search
The following pages link to Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. (Q34483086):
Displaying 50 items.
- Casein kinase 1 alpha 1 (Q21107836) (← links)
- Damage specific DNA binding protein 1 (Q21108214) (← links)
- Cereblon (Q21112029) (← links)
- F-box protein interactions with the hallmark pathways in cancer (Q26785368) (← links)
- Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase (Q27704179) (← links)
- A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase (Q27713259) (← links)
- Establishment of a Wheat Cell-Free Synthesized Protein Array Containing 250 Human and Mouse E3 Ubiquitin Ligases to Identify Novel Interaction between E3 Ligases and Substrate Proteins (Q28552579) (← links)
- Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends (Q30235355) (← links)
- Treatment of low-risk myelodysplastic syndromes (Q30240278) (← links)
- Established and emerging targeted therapies in the myelodysplastic syndromes (Q30245476) (← links)
- Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts (Q30249108) (← links)
- Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies (Q30249259) (← links)
- Selective degradation of splicing factor CAPERα by anticancer sulfonamides (Q33112699) (← links)
- Myelodysplastic syndromes: Contemporary review and how we treat (Q33429195) (← links)
- Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide (Q33438158) (← links)
- p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates (Q33556826) (← links)
- Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies (Q33574178) (← links)
- The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia (Q33796552) (← links)
- Induced protein degradation: an emerging drug discovery paradigm (Q34545841) (← links)
- Clonal evolution in myelodysplastic syndromes (Q34555597) (← links)
- Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells (Q36274044) (← links)
- The novel mechanism of lenalidomide activity. (Q36301512) (← links)
- Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway (Q36309724) (← links)
- SPLINTS: small-molecule protein ligand interface stabilizers (Q36805591) (← links)
- Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (Q36956452) (← links)
- Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. (Q37014078) (← links)
- Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion (Q37075929) (← links)
- In silico analysis of enantioselective binding of immunomodulatory imide drugs to cereblon (Q37104408) (← links)
- Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production (Q37281544) (← links)
- Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms (Q37299013) (← links)
- Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways (Q37716402) (← links)
- Therapy-related myeloid neoplasms: when genetics and environment collide (Q38611096) (← links)
- Natural products against hematological malignancies and identification of their targets (Q38632963) (← links)
- Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. (Q38644259) (← links)
- Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help? (Q38716306) (← links)
- Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase (Q38721357) (← links)
- β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q). (Q38727081) (← links)
- Ohgata, the Single Drosophila Ortholog of Human Cereblon, Regulates Insulin Signaling-dependent Organismic Growth (Q38739915) (← links)
- Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications (Q38758162) (← links)
- A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes (Q38764824) (← links)
- The ubiquitin ligase STUB1 regulates stability and activity of RUNX1 and RUNX1-RUNX1T1. (Q38768286) (← links)
- Emerging biological therapies for the treatment of myelodysplastic syndromes (Q38834981) (← links)
- Cereblon in health and disease (Q38876495) (← links)
- Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome (Q38905610) (← links)
- Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. (Q38909210) (← links)
- The molecular mechanism of thalidomide analogs in hematologic malignancies (Q38919111) (← links)
- Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction (Q38947679) (← links)
- Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings (Q38961023) (← links)
- Targeted Protein Degradation by Small Molecules (Q38978952) (← links)
- Emerging Methods in Chemoproteomics with Relevance to Drug Discovery (Q38997223) (← links)